


ADC ASIA
CONGRESS 2027

EBOOK

A Comprehensive
List of

166 ADC Companies in APAC

Your Essential Directory
of Antibody–Drug Conjugate
Innovators Across Asia Pacific



INTRODUCTION

From a Western-led field to a *region-wide industry*

Antibody-drug conjugates have moved from a niche modality to one of oncology's most closely watched drug classes, and nowhere is that shift more visible than in the Asia-Pacific region. What was once a field dominated by a handful of Western originators is now shaped just as much by biotechs in Shanghai, Hangzhou, Seoul and Taipei — many of which are now licensing their assets to the same multinational pharma companies that once set the pace.

This ebook maps that landscape. It brings together 166 companies across APAC that are actively developing, manufacturing or advancing ADC therapeutics — from established pharmaceutical players to emerging biotechs, research institutes and platform-technology innovators. The list spans Australia, China, Hong Kong, India, Japan, Malaysia, Singapore, South Korea, Taiwan and Thailand, reflecting how broadly ADC capability has spread across the region rather than staying concentrated in one or two hubs.

Compiled as an update to our previous regional mapping, this edition reflects how quickly the space continues to move: new entrants, licensing activity and manufacturing investment have reshaped the competitive picture in the past year alone.

INSIDE THIS REPORT

01	Industry updates — what is driving ADC momentum in APAC	03
02	Market map — where the 166 companies sit	04
03	The directory — all 166 companies by market	05
04	ADC Asia Congress 2027	06

INDUSTRY UPDATES

What is driving *ADC momentum in APAC*

01 China's ADC assets are commanding record licensing deals.

MediLink Therapeutics' partnership with Roche illustrates the scale of interest in China-originated ADC science: after an initial 2024 collaboration on the cMET-targeted YL211, the two companies expanded their agreement in early 2026 to cover YL201, with near-term payments alone reaching up to \$570 million plus further development and commercial milestones. Deals of this size have become a pattern rather than an exception for Chinese ADC originators.

02 Combination strategies are opening a new front in small cell lung cancer.

In April 2026, Zai Lab announced a global clinical collaboration with Amgen to test its DLL3-targeting ADC, zocilurtatug pelitecan, alongside Amgen's bispecific T-cell engager lmdelltra in extensive-stage small cell lung cancer — a signal that ADCs are increasingly being developed for combination use rather than as standalone therapies.

03 Novel linker-payload architecture is differentiating next-generation candidates.

At AACR 2026, Sichuan Kelun-Biotech's nectin-4-directed ADC (developed with Merck) showed a distinct responder profile compared to existing approved therapies, attributed to its bifunctional linker and pH-sensitive payload release — underscoring how much competitive advantage is now being built at the chemistry level rather than the target level alone.

04 Regulatory approvals are validating China's domestic ADC pipeline.


In May 2025, Jiangsu Hengrui Pharmaceuticals received NMPA approval for trastuzumab rezetecan in unresectable, locally advanced or metastatic NSCLC — one of a growing number of Chinese-originated ADCs to clear domestic regulatory approval and reach patients, rather than remaining licensed-out pipeline assets.

05 Manufacturing capacity is scaling to meet regional pipeline growth.

Samsung Biologics has moved decisively into dedicated ADC manufacturing, bringing a new ADC-specific production facility online and completing its first commercial-scale ADC engineering run in 2026, alongside plans for a third Bio Campus supporting ADCs, antibody vaccines, and cell and gene therapies — reflecting how manufacturing investment across APAC is racing to keep pace with the region's expanding ADC pipeline.

WHERE THE COMPANIES SIT

166 companies across 10 APAC markets



CHINA

76 of the 166 companies listed — the centre of gravity for ADC origination, licensing and clinical development in the region.

KOREA, TAIWAN & JAPAN

59 companies combined, strong in payload chemistry, conjugation platforms and dedicated ADC manufacturing.

THE REST OF APAC

31 companies across Australia, India, South-East Asia and Hong Kong — research institutes, CDMOs and emerging biotechs.

Company logos are shown where the IMAPAC partner library holds one; the remainder carry a monogram. Inclusion reflects publicly reported ADC development, manufacturing or platform activity.

THE DIRECTORY

All 166 ADC companies, by market

Shaded on the map behind: the darker the market, the more of these companies it holds.

 China

76

- Adagene
- AkesoBio
- Alphamab Oncology
- Antegene
- Arrivent
- Beigene
- BioCity Biopharma
- Biocytogen Pharmaceuticals
- BioNova Pharmaceuticals
- Bioray Pharmaceuticals
- Bio-Thera Solutions
- Biotheus
- BlissBio
- CASI Pharmaceuticals
- Chaingen Bio
- ConjuStar
- CSPC Pharmaceutical
- CStone Pharmaceuticals
- Duality Biologics
- Escugen
- Essex Biotechnology
- Fosun Pharma
- Fudan-Zhangjiang Bio-Pharmaceutical
- GeneQuantum Healthcare
- Genor Biopharma
- GlycanLink Biotech
- Hangzhou DAC Biotech Co Ltd
- Hansoh Pharma
- Harbour Biomed
- Henlius
- Hexin-med
- I-Mab Biopharma
- Innolake Biopharm
- Innovent Biologics Inc
- Inxmed
- Jiangsu Hengrui Pharmaceuticals Co
- Keymed Biosciences
- Klus Pharma
- LaNova
- Legend Biotech
- Lepu Biopharma
- MediLink Therapeutics
- Multitude Therapeutics
- neoX Biotech
- NKDbio
- Nona Biosciences
- Novelty Nobility
- NovoCodex Biopharmaceuticals
- Onward Therapeutics
- Phanes Therapeutics, Inc.
- PharmaEssentia Corporation
- PrimeLink Bio
- ProfoundBio
- Qilu Pharmaceutical
- RemeGen Co. Ltd
- Sanyou Bio
- Shanghai Affinity Biopharmaceutical
- Shanghai Junshi Biosciences Co., Ltd
- Shanghai Miracogen Inc.
- Shenzhen Enduring Biotech
- Sichuan Biokin Pharmaceuticals Co
- Sichuan Kelun-Biotech
- Sino Biopharmaceutical
- Sinocelltech
- Sunshine Guojian
- SystImmune
- Tavotek Biotherapeutics
- Teruisi Pharmaceutical
- Transcenta
- XILING LAB
- xzenith Biopharm
- Zai Lab
- Zhejiang Medicine Co. Ltd.
- Zhejiang Zova Biotherapeutic
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Zymeworks Inc

**South Korea**

28

- AbbVie Korea
- Abclon
- ABL Bio
- AbTis
- Aimed bio
- Alteogen
- CrossPoint Therapeutics
- Daewong Pharmaceutical
- Donga ST
- Edis Biotech
- Hanmi Pharmaceutical
- ImmunoGen, Inc.
- IMNEWRUN
- Intocell
- Intocell Inc
- ISU Abxis
- Kanaph Therapeutics Inc
- LegoChem Biosciences
- Medytox
- Orum Therapeutics
- Pepttron
- Pinot Bio
- Prestige Biopharma
- ProAbTech
- Progen
- Samsung Biologics
- SK Bioscience
- Y Biologics

 Taiwan

17

- Adenovation Biotech
- Development Center of Biotechnology
- EirGenix
- Everest Medicines
- Formosa Lab
- Glyconex
- Hanchor Bio
- Haplogen Inc.
- Honeybear Biosciences
- Immunwork
- OBI Pharma
- SCI Pharmatech
- TaiGen Biotechnology Co. Ltd
- Taimed Biologics
- Taiwan Biopharma Co. Ltd
- T-E Meds
- TWI Biotechnology, Inc.

 Japan

14

- Asahi Kasei Pharma Corporation
- Astellas Pharma
- Chiome Bioscience
- Chugai Pharma
- Daiichi Sankyo
- Eisai
- Kyowa Kirin Co., Ltd
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- PeptiDream Inc.
- Rakuten Medical
- RIN Institute
- Sumitomo Pharma
- Takeda

 Australia

10

- Carina Biotech
- Imugene Limited
- Ipsen
- Monash Biomedical Imaging (MBI)
- OncoOne
- Peter MacCallum Cancer Centre
- Telix Pharmaceuticals
- University of Melbourne
- Zelda Therapeutics
- ZyBio

 India

8

- Bharat Serums and Vaccines
- Biocon Biologics
- Dr. Reddy's Laboratories
- Intas Pharmaceuticals
- Lupin Pharmaceuticals
- Reliance Life Sciences
- Sun Pharma Advanced Research Company Ltd.
- Zydus Cadila

 Thailand

6

- Baiya Phytopharm
- BioNet Asia
- Biovac
- GPO
- Siam Bioscience
- Zyrex

 Singapore

4

- Axcynsis Therapeutics
- DotBio
- Hummingbird Bioscience
- NeoGlyco Therapeutic

 Malaysia

2

- Biocon Sdn Bhd
- Pharmaniaga

 Hong Kong

1

- Arbele Bio

MEET THEM IN PERSON

The companies building Asia-Pacific's antibody-drug conjugate pipeline

The 166 organisations in this report represent the breadth of ADC activity across APAC — originators, CDMOs, payload and linker specialists, and the research institutes behind the next wave of candidates.

ADC Asia Congress 2027 brings them together with the technology providers, manufacturers and clinical teams shaping how these therapies reach patients.

ADC Asia Congress 2027

Uniting Asia's leaders in antibody-drug conjugates

23–24 March 2027

Sands Expo & Convention Centre, Singapore

Part of Biopharma APAC Confex 2027

Payload & linker chemistry

Conjugation & CMC

Clinical development

Manufacturing & supply

Join ADC Asia Congress 2027.

Connect with the originators, manufacturers and technology partners driving ADCs across Asia-Pacific.

